Unlocking Unprecedented Value: The Advent of the Established Brand
Established Brands – inclusive of both core brands late in their lifecycle and non-core assets in their prime – can represent a significant source of revenue for pharmaceutical companies and still deliver critical and ongoing therapeutic value to patients. This class is often supported by only minimal sales and marketing efforts, while facing challenges such as resource reprioritization, clinical advancements and patent urgency.
The key to maximizing the revenue potential of Established Brands is to implement highly targeted but low-cost customer engagement programs that drive sales with less effort, but much greater impact.
Download the full white paper using the link below.